RXSTRxSight Inc. Common Stock

Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). By pairing RxSight’s proprietary light-adjustable technology, which allows eye surgeons to […]

Alcon partnership revenue offsets 19% product sales decline from competitive pressure.

RxSight Inc (RXST) navigates a challenging quarter with a 19% product sales drop while securing a transformative $200 million Alcon collaboration and planning to double its U.S. sales team.

RxSight (NASDAQ:RXST) reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the b

RxSight (RXST) delivered earnings and revenue surprises of +47.62% and +2.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

UFP (UFPT) delivered earnings and revenue surprises of +16.34% and +8.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RxSight’s latest valuation work has taken the modelled fair value from US$9.93 to US$8.43, which points to a refreshed view of what the stock may be worth under updated assumptions. Analysts are linking this reset to softer recent Q2 trends, revised guidance, and the timing of potential contributions from the new Alcon collaboration. As you read on, you will see how these moving parts are shaping the evolving RxSight story and what to watch next in the analyst narrative. Stay updated as the...

RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.